




Patent N° WO 2005/048968

MATRIXYL™ 3000



Pal-GHK and Pal-GQPR

Function:

Anti-wrinkling and lifting effect.

Definition:

Matrixyl™3000 contains two matrikines™, Pal-GHK and Pal-GQPR which act in synergy to restore and maintain skin's youthful appearance.

Properties:

Matrixyl™3000 contains matrikines which are messengers of cutaneous restructuring and repair. They activate the neosynthesis of extracellular matrix macromolecules providing Matrixyl™3000 with a visible anti-wrinkle efficacy.

Characteristics:

As messenger molecules, matrikines™ are capable of regulating cell activities. They interact with specific receptors to activate certain genes involved in the process of extracellular matrix renewal and cell proliferation. With age these mechanisms become progressively weaker.

INCI Name:

(Check CTFA on-line dictionary for latest INCI name)

Glycerin – Aqua (Water)

– Butylene Glycol

– Carbomer – Polysorbate

20 – Palmitoyl Oligopeptide

– Palmitoyl Tetrapeptide-7*

* former INCI name: Palmitoyl Tetrapeptide-3

Applications:

Anti-aging , face lifting and wrinkle treatment products. Suitable for gels, serums lotion, creams.

Formulation:

Water soluble.

Recommended use level:

3% to 8%



45% less wrinkles in 2 months



Lifetime youth



Member of Croda International Plc

Copyright © 2006 Sederma. All rights reserved

www.sederma.fr

E-mail: sederma@sederma.fr


In vitro tests

● Synthesis of matrix macromolecules

Study to determine ability of fibroblasts incubated for 72 hours with Matrixyl™3000 (1, 3, and 5%) to stimulate synthesis of extracellular matrix components.

● Stimulation of gene expression

Study to evaluate regulation of dermal and epidermal genes by matrikines present in Matrixyl™3000, using DNA-Array techniques on a reconstructed epidermis and a fibroblast culture.



The profile of gene activation by the matrikines™ in Matrixyl™3000 complement the skin's natural mechanisms for cutaneous restructuring.

In vivo tests

● Visible and measurable proof of anti-wrinkle efficacy


Clinical study in which 2 panels of 23 volunteers aged 39 to 74 applied a cream containing 3% Matrixyl™3000 to one-half of their face against a placebo or 3% Matrixyl™ on the other half, twice a day for 56 days. Anti-wrinkling and lifting efficacy was assessed by profilometry and photography, as compared to T0.

Variation of parameters compared to T0 (%)			
	Matrixyl™3000	Matrixyl™	Placebo
Surface occupied by deep wrinkles (>200µm)	- 44.9**	- 27.7**	4.3ns
Main wrinkle density	- 37.0**	- 27.3*	- 9.6ns
Main wrinkle average depth	- 15.1**	- 9.8**	- 3.2ns
Main wrinkle average volume	- 18.5**	- 14.7**	- 8.7*
Roughness	- 14.4**	- 10.8**	1.4ns
Complexity (Lifting effect)	- 16.6**	- 12.7**	4.2ns

ns: non significant *significant / T0 (p<0.05) **significant / T0 (p<0.01)

● Effect on skin elasticity and tone

Assessment of elasticity and tone by cutometry on the same panel as above.



Matrixyl™3000 displays major and significant improvements in elasticity and tone.



Non-warranty: The information in this publication is given in good faith by Sederma by way of general guidance and for reference purposes only. The information should not be construed as granting a license to practice any methods or compositions of matter covered by patents. Sederma assumes no liability in relation to the information and gives no warranty regarding the suitability of the product and/or ingredients described for a particular use. The use made of the product and/or ingredients described by the recipient and any claims or representations made by the recipient in respect of such product and/or ingredients are the responsibility of the recipient. The recipient is solely responsible for ensuring that products marketed to consumers comply with all relevant laws and regulations.